Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TSS
MCID: TXC005
MIFTS: 62

Toxic Shock Syndrome (TSS)

Categories: Infectious diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Toxic Shock Syndrome

About this section

MalaCards integrated aliases for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 74 54 15 71 32
Septic Shock 17 32
Staphylococcal Toxic Shock Syndrome 71
Shock, Septic 44
Toxic Shock 12
Tss 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:14115
ICD9CM 34 040.82
MeSH 44 D012772
NCIt 50 C35498
SNOMED-CT 67 18504008
ICD10 32 A48.3 R57.2
UMLS 71 C0600327 C3714602
Sources

Summaries for Toxic Shock Syndrome

About this section
Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as septic shock, is related to staphylococcal toxic shock syndrome and streptococcal toxic-shock syndrome, and has symptoms including hypotension, vomiting and fever. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Milrinone and Protein C have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and neutrophil, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Sources

Related Diseases for Toxic Shock Syndrome

About this section

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1227)
# Related Disease Score Top Affiliating Genes
1 staphylococcal toxic shock syndrome 33.2 TNF IL1B IFNG HMGB1 CIITA
2 streptococcal toxic-shock syndrome 32.8 TNF MYOM2 LTA IL6 IL2 CXCL8
3 exanthem 31.7 TNF IL6 IL2 IL1B IL10 IFNG
4 pharyngitis 31.4 TNF MYOM2 IL6 IL1B CXCL8
5 scarlet fever 31.4 TNF MYOM2 EDNRA
6 necrotizing fasciitis 31.3 MYOM2 LTA IL6 IL2 IL1RN IL1B
7 cellulitis 31.3 TNF MYOM2 IL6
8 disseminated intravascular coagulation 31.3 TNF SERPINC1 IL6 IL10 HMGB1
9 fasciitis 31.2 TNF MYOM2 LTA IL6 IL2 IL1RN
10 kawasaki disease 31.2 TNF IL6 IL4 IL1B IL10
11 neisseria meningitidis infection 31.2 TLR4 TLR2 IL1RN
12 tracheitis 31.1 TNF IL6 IL1B CXCL8
13 acute pyelonephritis 31.1 IL6 IL10 CXCL8
14 chickenpox 31.1 TNF IL6 IL4 IL2 IL10 IFNG
15 myositis 31.1 TNF IL6 IL2 IL1B IFNG CXCL8
16 lymphopenia 31.0 IL6 IL4 IL2 IL10 IFNG
17 bursitis 31.0 TNF IL6 IL1B
18 stevens-johnson syndrome/toxic epidermal necrolysis 31.0 IL2 IFNG HMGB1
19 congestive heart failure 30.9 TNF IL6 IL1B EDNRA
20 vaginal discharge 30.9 TNF IL6 IL1B IL10 CXCL8
21 endometritis 30.9 TNF TLR4 IL6 IL1B CXCL8
22 impetigo 30.9 MYOM2 IL6 EDNRA
23 arthropathy 30.8 TNF LTA IL6 IL1B IFNG
24 purpura 30.8 TNF SERPINC1 IL6 IL4 IL1B IL10
25 hypereosinophilic syndrome 30.8 IL4 IL2 IL10 IFNG CXCL8
26 pustulosis of palm and sole 30.7 TNF IL1RN CXCL8
27 chikungunya 30.7 TNF IL6 IL1B
28 vaginitis 30.7 TNF TLR2 IL6 IL1B IL10 CXCL8
29 diarrhea 30.7 TNF TLR4 IL6 IL2 IL1B IL10
30 pain agnosia 30.7 TNF IL6 IL1B
31 adult respiratory distress syndrome 30.7 TNF LBP IL6 IL1RN IL1B IL10
32 intestinal perforation 30.7 TNF TLR4 IL6
33 mastitis 30.7 TLR2 LBP IL6 IL1RN EDNRA CXCL8
34 compartment syndrome 30.7 TNF SERPINC1 IL6
35 human cytomegalovirus infection 30.7 IL6 IL1B CXCL8
36 dysentery 30.7 TNF IL6 IL1B IL10 CXCL8
37 meningoencephalitis 30.7 TNF IL6 IL10
38 pancreatitis 30.7 TNF IL6 IL1B IL10
39 pulmonary hypertension 30.7 TNF TLR4 SERPINC1 IL6 IL1B IL10
40 diphtheria 30.7 TNF IL4 IL2 IL1B IFNG
41 septic arthritis 30.7 TREM1 TLR4 TLR2 IFNG CXCL8
42 ileus 30.6 TNF IL6 IL1B IL10
43 acute cystitis 30.6 TNF TLR4 IL6 IL1B IL10 CXCL8
44 cystitis 30.6 TNF TLR4 IL6 IL4 IL2 CXCL8
45 varicose veins 30.6 TNF SERPINC1 IL6 CXCL8
46 conjunctivitis 30.6 TNF IL6 IL4 IL2 IL10 IFNG
47 orchitis 30.6 TNF IL6 IL2 IL1B IL10
48 pelvic inflammatory disease 30.6 TLR4 TLR2 IL2 IFNG
49 lupus erythematosus 30.6 TNF IL10 IFNG HMGB1 CD86
50 acquired immunodeficiency syndrome 30.6 TNF IL6 IL2 IL1B IL10 IFNG

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome
Sources

Symptoms & Phenotypes for Toxic Shock Syndrome

About this section

Symptoms:

12
  • • hypotension
  • • vomiting
  • • fever
  • • headache
  • • diarrhea
  • • rash
  • • multiorgan failure
  • • desquamation
  • • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 CD86 CIITA EDNRA IFNG IL10 IL1B
2 homeostasis/metabolism MP:0005376 10.41 CD86 CIITA EDNRA IFNG IL10 IL1B
3 immune system MP:0005387 10.39 CD86 CIITA EDNRA IFNG IL10 IL1B
4 cardiovascular system MP:0005385 10.34 EDNRA IFNG IL10 IL1B IL1RN IL2
5 cellular MP:0005384 10.33 CD86 EDNRA IFNG IL10 IL1RN IL2
6 growth/size/body region MP:0005378 10.32 EDNRA IFNG IL10 IL1B IL1RN IL2
7 endocrine/exocrine gland MP:0005379 10.26 CD86 CIITA EDNRA IFNG IL10 IL2
8 digestive/alimentary MP:0005381 10.19 EDNRA IFNG IL10 IL2 IL4 IL6
9 integument MP:0010771 10.17 EDNRA IFNG IL10 IL1B IL1RN IL4
10 liver/biliary system MP:0005370 10.14 IFNG IL10 IL2 IL4 IL6 LBP
11 nervous system MP:0003631 10.03 CD86 EDNRA IFNG IL10 IL1B IL4
12 muscle MP:0005369 10.02 CD86 EDNRA IFNG IL10 IL6 SERPINC1
13 neoplasm MP:0002006 9.97 IFNG IL10 IL1B IL2 IL6 TLR2
14 respiratory system MP:0005388 9.85 EDNRA IFNG IL10 IL2 IL4 IL6
15 skeleton MP:0005390 9.77 CIITA EDNRA IFNG IL10 IL1B IL1RN
16 vision/eye MP:0005391 9.36 EDNRA IFNG IL10 IL2 IL4 IL6
Sources

Drugs & Therapeutics for Toxic Shock Syndrome

About this section

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milrinone Approved Phase 4 78415-72-2 4197
2
Protein C Approved Phase 4
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
7
Succinylcholine Approved Phase 4 306-40-1 5314
8
Simvastatin Approved Phase 4 79902-63-9 54454
9
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
10
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
11
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
12
Dalteparin Approved Phase 4 9005-49-6
13
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
16
Propafenone Approved Phase 4 54063-53-5 4932
17
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
18
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
19
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
22
Clarithromycin Approved Phase 4 81103-11-9 84029
23
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
24
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
25
Lopinavir Approved Phase 4 192725-17-0 92727
26
Azithromycin Approved Phase 4 83905-01-5 55185 447043
27
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
28
Ticagrelor Approved Phase 4 274693-27-5 9871419
29
Hydroxychloroquine Approved Phase 4 118-42-3 3652
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
32
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
33
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
34
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
35
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
36
Racepinephrine Approved Phase 4 329-65-7 838
37
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
38
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
39
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
40
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
41
Tazobactam Approved Phase 4 89786-04-9 123630
42
Piperacillin Approved Phase 4 66258-76-2 43672
43
Phenylephrine Approved Phase 4 59-42-7 6041
44
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
45
Ephedrine Approved Phase 4 299-42-3 9294
46
Pseudoephedrine Approved Phase 4 90-82-4 7028
47
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
48
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
49
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
50
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 628)
# Name Status NCT ID Phase Drugs
1 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4 Simvastatin
2 The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation Unknown status NCT02612363 Phase 4 Dexmedetomidine for sedation
3 The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study Unknown status NCT02612181 Phase 4 Dexmedetomidine for dexmedetomidine group
4 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
5 COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU Unknown status NCT01639664 Phase 4
6 Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study Unknown status NCT03336814 Phase 4 Terlipressin
7 A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock Unknown status NCT00837057 Phase 4
8 Effects of Vitamin C, Thiamine and Hydrocortisone in Septic Shock: a Randomized, Controlled Trial Unknown status NCT04039815 Phase 4 Ascorbic acid-Vitamin B1-Hydrocortisone;Placebo
9 Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial Completed NCT00273728 Phase 4 hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
10 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis Completed NCT01310790 Phase 4
11 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
12 Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients Completed NCT00763906 Phase 4
13 Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis Completed NCT02730624 Phase 4 Piperacillin-tazobactam
14 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
15 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
16 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4 Recombinant Activated Protein C;Phenylephrine
17 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4 norepinephrine
18 The Effect of Fluids and Norepinephrine for Mean Arterial Pressure Titration to Patients' Usual Levels on the Microcirculation of Initial Resuscitated Hypertensive Septic Shock Patients. Completed NCT02085291 Phase 4 Norepinephrine;Crystalloid
19 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial Completed NCT02079402 Phase 4 Isotonic crystalloids
20 Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
21 A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock Completed NCT01448109 Phase 4 Hydrocortisone;Sterile air filled vial
22 Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock Completed NCT01188993 Phase 4
23 Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline Completed NCT00327704 Phase 4 albumin;saline
24 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial Completed NCT03120637 Phase 4 Methylene Blue
25 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4 Meropenem
26 Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients Completed NCT02270281 Phase 4 Dexmedetomidine 0.7 Mcg/kg/h
27 Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients Completed NCT03911817 Phase 4 Midodrine
28 Ketamine-based Versus Opioid-based for Rapid-sequence Induction of Anesthesia in Patients With Septic Shock Completed NCT03251170 Phase 4 Ketamine;Fentanyl;Midazolam
29 Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults Completed NCT04492280 Phase 4 Hydrocortisone
30 An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock Completed NCT00279214 Phase 4 drotrecogin alfa (activated)
31 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
32 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
33 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED) Completed NCT02365272 Phase 4 Amikacin
34 Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY Completed NCT00329680 Phase 4
35 A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China Recruiting NCT02647554 Phase 4 ulinastatin;Placebo
36 Comparison of Extubation Delay After Prolonged Sedation With Inhaled Isoflurane Using the MIRUS® Device or Continuous Intravenous Midazolam in Patients With Septic Shock in Intensive Care Recruiting NCT04710914 Phase 4 Prolonged sedation with isoflurane;Prolonged sedation with midazolam
37 Renin and Renal Biomarker Response to Angiotensin II Versus Controls in Septic Shock: An Open-Label Study Recruiting NCT04558359 Phase 4 Angiotensin II
38 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial Recruiting NCT03668236 Phase 4 Isotonic crystalloids
39 Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock Recruiting NCT03029169 Phase 4 Propafenone i.v.;Amiodarone i.v.
40 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Fixed-duration Hydrocortisone;Shock-dependent hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin-tazobactam;Ceftaroline;Amoxicillin-clavulanate;Macrolide administered for 3-5 days;Macrolide administered for up to 14 days;Five-days oseltamivir;Ten-days oseltamivir;Lopinavir/ritonavir;Hydroxychloroquine;Hydroxychloroquine + lopinavir/ritonavir;Interferon-β1a;Anakinra;Fixed-duration higher dose Hydrocortisone;Tocilizumab;Sarilumab;Vitamin C;Therapeutic anticoagulation;Simvastatin;Eritoran;Apremilast;Aspirin;Clopidogrel;Prasugrel;Ticagrelor
41 Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) Recruiting NCT03068741 Phase 4 Comparison 1: Prehospital Ceftriaxone;Comparison 1: Placebo;Comparison 2: Liberal fluids;Comparison 2: Conservative fluids
42 Limiting AKI Progression In Sepsis (LAPIS): A Phase 4, Multicenter, Randomized Controlled Trial of Biomarker-guided Delivery of Kidney-sparing Care Measures in Sepsis Subjects at Risk of Developing AKI Recruiting NCT04434209 Phase 4
43 Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial Not yet recruiting NCT02899702 Phase 4 PRIVIGEN (CSL Behring);Albumin
44 Effects of Low-chlorine Vs High-chlorine Crystalloid Solutions in Septic Shock Adults Not yet recruiting NCT04365010 Phase 4 Sodium Bicarbonate Ringer's Injection;0.9% Sodium Chloride Injection
45 The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation, a Preplanned Substudy of the CLASSIC Trial Not yet recruiting NCT04282252 Phase 4 I.V. SOLUTIONS
46 Hupophosphatemia Levels Deleteriously Affect Outcome of Patients With Severe Sepsis/Septic Shock Admitted to ICU Not yet recruiting NCT04519762 Phase 4 Glycophos (Sodium Glycerophosphate);Antibiotics;Inotropes
47 The Impact of Optimized Caloric-proteic Nutrition on Clinical Outcome and Physical Component Summary (PCS) of Quality of Life in Septic and Septic Shock Patients Suspended NCT02731144 Phase 4
48 A Multi-center Randomized Comparison of a Minimally-invasive Cardiovascular Hemodynamic Optimization (MiCHO) Protocol Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock Patients Presenting to the Emergency Department Terminated NCT00535821 Phase 4
49 A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients Terminated NCT02203630 Phase 4 Phenylephrine;Norepinephrine
50 An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock Terminated NCT00842933 Phase 4 Corticosteroid;Corticosteroid

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Sources

Genetic Tests for Toxic Shock Syndrome

About this section
Sources

Anatomical Context for Toxic Shock Syndrome

About this section

MalaCards organs/tissues related to Toxic Shock Syndrome:

40
Kidney, Endothelial, Neutrophil, Skin, Monocytes, Myeloid, T Cells
Sources

Publications for Toxic Shock Syndrome

About this section

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 26627)
# Title Authors PMID Year
1
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 6 54 61
10450718 1999
2
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
5
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 6
14718719 2004
6
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
7
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
8
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
9
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
10
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
11
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
12
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
13
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
14
Why not treat human cancer with interleukin-1 blockade? 54 61
20422276 2010
15
Spectrum of sepsis, mediators, source control and management of bundles. 61 54
20515762 2010
16
Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. 54 61
20421309 2010
17
The septic shock-associated IL-10 -1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. 54 61
20181890 2010
18
Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. 61 54
19789465 2010
19
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. 61 54
20154607 2010
20
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. 54 61
20119647 2010
21
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. 54 61
19717486 2010
22
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 54 61
20004006 2010
23
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. 61 54
20051843 2010
24
Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions. 54 61
19536045 2010
25
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 61 54
20192933 2010
26
Immunogenicity of toxins during Staphylococcus aureus infection. 61 54
19947854 2010
27
Toll-like receptor 4 modulation as a strategy to treat sepsis. 54 61
20396414 2010
28
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. 61 54
20165718 2010
29
[Gene polymorphisms of Toll-like receptors in Chinese Han children with sepsis in Wenzhou]. 54 61
20441696 2010
30
Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. 61 54
20181046 2010
31
Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. 61 54
20472994 2010
32
beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. 61 54
19850944 2010
33
Evidence lost to treatment of critically-ill patients? 54 61
19940825 2009
34
Sick adrenal or sick euadrenal? 54 61
20001882 2009
35
Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study. 61 54
20021698 2009
36
Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber. 61 54
19954476 2009
37
Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6, and 10 in patients with sepsis and septic shock. 61 54
19327330 2009
38
Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. 61 54
19760208 2009
39
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. 61 54
19450686 2009
40
Early suspension of activated protein C treatment in septic patients after shock reversal. 61 54
19474736 2009
41
Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. 54 61
19793001 2009
42
Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. 61 54
20146868 2009
43
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. 54 61
19652948 2009
44
C-reactive protein is not a useful indicator for infection in surgical intensive care units. 54 61
20512289 2009
45
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. 54 61
19740375 2009
46
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss. 54 61
19596611 2009
47
Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. 54 61
19551369 2009
48
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy. 61 54
19698279 2009
49
Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats. 54 61
18848768 2009
50
Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock. 61 54
19062078 2009
Sources

Variations for Toxic Shock Syndrome

About this section

ClinVar genetic disease variations for Toxic Shock Syndrome:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TNF TNF, -308G-A SNV risk factor 12388
Sources

Expression for Toxic Shock Syndrome

About this section
Search GEO for disease gene expression data for Toxic Shock Syndrome.
Sources

Pathways for Toxic Shock Syndrome

About this section

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.14 TREM1 TNF TLR4 TLR2 LTA LBP
2
PEDF Induced Signaling 63
Show member pathways
 13.81 TNF TLR4 LTA IL6 IL4 IL2
3
TGF-Beta Pathway 63
Show member pathways
 13.65 TNF LTA IL6 IL4 IL2 IL1B
4
Akt Signaling 63
Show member pathways
 13.56 TNF TLR4 TLR2 LTA IL6 IL4
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.48 TNF LTA LBP IL6 IL4 IL2
6
PAK Pathway 63
Show member pathways
 13.42 TNF LTA IL6 IL4 IL2 IL1B
7
IL-2 Pathway 63
Show member pathways
 13.37 TREM1 TNF TLR4 TLR2 LBP IL4
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.18 TREM1 TNF TLR4 TLR2 LBP IL6
9
PI3K-Akt signaling pathway 36
Show member pathways
 13.08 TNF TLR4 TLR2 IL6 IL4 IL2
10
Human cytomegalovirus infection 36
Show member pathways
 13.08 TNF TLR4 TLR2 IL6 IL1B CXCL8
11
Measles 36
Show member pathways
 13.01 TNF TLR4 TLR2 IL6 IL2 IL1B
12
Pathways in cancer 36
12.96 IL6 IL4 IL2 IFNG EDNRA CXCL8
13
Allograft rejection 36 1
Show member pathways
 12.94 TNF LTA IL6 IL4 IL2 IL1B
14
Herpes simplex virus 1 infection 36
12.92 TNF TLR2 LTA IL6 IL1B IFNG
15
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.89 TNF TLR4 TLR2 IL6 IL1RN IL1B
16
Salmonella infection (KEGG) 36
Show member pathways
 12.87 TNF TLR4 TLR2 IL6 IL1B CXCL8
17
NF-KappaB Family Pathway 63
Show member pathways
 12.87 TNF TLR4 TLR2 LTA IL6 IL2
18
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways